Updated on 2026/03/24

写真a

 
ADACHI Shiro
 
Organization
Nagoya University Hospital Cardiology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor
Profile
I am engaged in clinical practice and research in pulmonary hypertension, including both clinical and basic science studies. We also actively perform balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension. Our dedicated pulmonary hypertension team works collaboratively to advance both patient care and research.
External link

Degree 1

  1. 博士(医学) ( 2016.3   名古屋大学 ) 

Research Interests 4

  1. Pulmonary hypertension

  2. CTEPH

  3. 右心不全

  4. PH crisis

Research History 3

  1. Nagoya University   Nagoya University Hospital Cardiology   Assistant Professor

    2025.1

  2. Nagoya University   Assistant Professor of Hospital

    2019.2 - 2024.12

  3. Nagoya University   Graduate School of Medicine

    2012.4 - 2016.3

Education 1

  1. Nagoya University   Graduate School, Division of Medical Sciences

    2016.3

      More details

    Country: Japan

Professional Memberships 3

  1. 日本肺高血圧肺循環学会

  2. 日本内科学会

  3. 日本循環器学会

Awards 1

  1. 若手・研修医セッション2 最優秀賞 指導医

    2025.10   日本循環器学会   TBX4の遺伝学的異常が判明した家族性肺動脈性肺高血圧症の一例

 

Papers 61

  1. A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial. Reviewed Open Access

    Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S, Murohara T, Hatano M, Tamura Y, Yamashita J, Tatsumi K, Tsujino I, Kobayakawa Y, Adachi S, Yaoita N, Minatsuki S, Todaka K, Fukuda K, Tsutsui H, Abe K; KABUKI Investigators.

    Circulation   Vol. 149 ( 5 ) page: 406 - 409   2024.1

     More details

  2. Outcomes of Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty and Pulmonary Endarterectomy. Reviewed Open Access

    Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, Adachi S, Inami T, Yamashita J, Ogino H, Tsujino I, Hatano M, Yaoita N, Ikeda N, Shimokawahara H, Tanabe N, Kubota K, Shigeta A, Ogihara Y, Horimoto K, Dohi Y, Kawakami T, Tamura Y, Tatsumi K, Abe K; CTEPH AC Registry Study Group.

    JACC Asia   Vol. 4 ( 8 ) page: 577 - 589   2024.8

     More details

  3. Prevalence, Clinical Features, and Treatment Response of Chronic Thromboembolic Pulmonary Hypertension in Patients With Myeloproliferative Neoplasm. Reviewed Open Access

    Hirose M, Nakano Y, Adachi S, Sugiyama T, Yoshida M, Murohara T

    Circulation reports   Vol. 8 ( 3 ) page: 486 - 494   2026.3

     More details

  4. Ray of Hope for Expanding Hemodynamics Estimation During Exercise Stress Testing in Patients With Pulmonary Hypertension. Reviewed Open Access

    Adachi S, Nakano Y, Hirose M

    Circulation journal : official journal of the Japanese Circulation Society   Vol. 90 ( 2 ) page: 232 - 233   2026.1

     More details

  5. Immunosuppressive Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases: Insights from Japanese Registry. Reviewed

    Tamura Y, Tamura Y, Takemura R, Taniguchi Y, Tsujino I, Inami T, Matsubara H, Shigeta A, Hatano M, Adachi S, Tahara N, Sakurai K, Horimoto K, Yaoita N, Abe K, Dohi Y, Kimura K, Kubota K, Kikuchi N, Yasuoka H, Baba Y, Shinke T, Amino M, Yamaguchi N, Ikeda S, Sato T, Ishida M, Sera F, Nakanishi N, Konishi H, Kinugawa K, Kashimura T, Dohi K, Nakamura K, Usui S, Tanaka S, Kubota S, Ikeda N, Yoshikawa M, Odagiri K, Tasaka S, Takeishi Y, Sugano T, Sugimura K, Tatsumi K, Kuwana M, Japan Pulmonary Hypertension Registry Network

    Advances in therapy   Vol. 42 ( 12 ) page: 6103 - 6117   2025.12

     More details

    Language:English  

    DOI: 10.1007/s12325-025-03389-z

    PubMed

  6. Long-term outcomes of Qing-Dai-induced pulmonary arterial hypertension. Reviewed Open Access

    Isobe S, Tu L, Dohi Y, Hiraide T, Adachi S, Komura N, Tsujino I, Inami T, Sera F, Kato Y, Hatano M, Ueno S, Ogo T, Orihara Y, Fujii H, Amano K, Montani D, Guignabert C, Humbert M, Tatsumi K, Tamura Y

    ERJ open research   Vol. 11 ( 6 )   2025.11

     More details

  7. Effects of pulmonary endarterectomy and balloon pulmonary angioplasty in older adults with chronic thromboembolic pulmonary hypertension: A sub-analysis of the CTEPH AC registry. Reviewed Open Access

    Yamashita J, Ogino H, Masaki K, Taniguchi Y, Adachi S, Inami T, Hosokawa K, Tsujino I, Yaoita N, Hatano M, Ikeda N, Tanabe N, Shimokawahara H, Kubota K, Shigeta A, Horimoto K, Ogihara Y, Dohi Y, Hiraide T, Kawakami T, Ikemiyagi H, Tamura Y, Fukumoto Y, Abe K, CTEPH AC Registry Study Group

    International journal of cardiology. Heart & vasculature   Vol. 60   page: 101751   2025.10

     More details

  8. Insights into balloon pulmonary angioplasty and the WHO functional class of chronic thromboembolic pulmonary hypertension patients: findings from the CTEPH AC registry Reviewed

    Nobutaka Ikeda 1, Kohei Masaki 2, Kazuya Hosokawa 2, Kouta Funakoshi 3, Yu Taniguchi 4, Shiro Adachi 5, Takumi Inami 6, Jun Yamashita 7, Hitoshi Ogino 8, Ichizo Tsujino 9, Masaru Hatano 10, Nobuhiro Yaoita 11, Hiroto Shimokawahara 12, Nobuhiro Tanabe 13, Kayoko Kubota 14, Ayako Shigeta 15, Yoshito Ogihara 16, Koshin Horimoto 17, Yoshihiro Dohi 18, Takashi Kawakami 19, Yuichi Tamura 20, Koichiro Tatsumi 15, Kohtaro Abe 2

    Cardiovasc Interv Ther .   Vol. 40 ( 3 ) page: 689 - 700   2025.7

     More details

    Language:English  

    DOI: 10.1007/s12928-025-01095-9

    PubMed

  9. Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment. Reviewed Open Access

    Satoh T, Tamura Y, Takama N, Matsubara H, Tanabe N, Inami T, Hiraide T, Abe K, Dohi Y, Ogihara Y, Ogo T, Adachi S, Nakazato K, Tsujino I, Ota H, Komaru K, Sato H, Tezuka Y, Ono Y, Suda R, Hosokawa K, Isobe S, Kiko T, Koga Y, Nakamura J, Sugimura K, Hatano M, Fukumoto Y, Yasuda S

    Pulmonary circulation   Vol. 15 ( 2 ) page: e70116   2025.4

     More details

  10. Cancer as an independent mortality risk in chronic thromboembolic pulmonary hypertension. Reviewed Open Access

    Nakamura J, Tsujino I, Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, Adachi S, Inami T, Yamashita J, Ogino H, Hatano M, Yaoita N, Ikeda N, Shimokawahara H, Tanabe N, Kubota K, Shigeta A, Ogihara Y, Horimoto K, Dohi Y, Kawakami T, Tamura Y, Tatsumi K, Abe K

    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation   Vol. 44 ( 3 ) page: 339 - 348   2025.3

     More details

  11. Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors Reviewed Open Access

    Yoshihisa Nakano 1 2, Shiro Adachi 3, Miku Hirose 4, Takeshi Adachi 2, Itsumure Nishiyama 4, Kenichiro Yasuda 2 5, Masahiro Yoshida 4 6, Takahisa Kondo 4 7, Toyoaki Murohara 4

    Sci Rep .   Vol. 14 ( 1 ) page: 25762   2024.10

     More details

  12. Controlling Nutritional Status Score Predicts 1-Year Outcomes in Chronic Thromboembolic Pulmonary Hypertension Invited Open Access

    Adachi Takeshi, Adachi Shiro, Nakano Yoshihisa, Nishiyama Itsumure, Hirose Miku, Murohara Toyoaki

    Circulation Reports   Vol. 6 ( 9 ) page: 381 - 388   2024.9

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b> The prognosis for patients with chronic thromboembolic pulmonary hypertension (CTEPH) using their nutritional status has not been established. We investigated the relationship between the prognosis of patients with CTEPH and the Controlling Nutritional Status (CONUT) score, which is a nutritional assessment tool.</p><p><b><i>Methods and Results:</i></b> A total of 157 patients with CTEPH was enrolled in the study. The primary outcome was defined as the composite outcome of all-cause mortality and non-elective hospitalization due to heart failure. Receiver operating characteristic (ROC) curve analysis was used to determine the cutoff CONUT score for predicting the 1-year rate of the primary outcome. Patients were divided into 2 groups according to the significant cutoff value and compared. Undernutrition was observed in 51.6% of patients. ROC analysis revealed a significant cutoff CONUT score of 3.5 (area under the curve=0.789). The incidence rate of the primary composite outcome was higher in the high CONUT group (score ≥4) than in the low CONUT group (score ≤3; 20% vs. 2.2%; P<0.001). Cox analysis revealed the CONUT score per point increase was an independent risk factor for the primary composite outcomes (hazard ratio 2.301; 95% confidence interval 1.081–4.895; P=0.031).</p><p><b><i>Conclusions:</i></b> The CONUT score can predict the 1-year rate of all-cause death and non-elective hospitalization in patients with CTEPH.</p>

    DOI: 10.1253/circrep.CR-24-0023

    Open Access

    PubMed

    CiNii Research

  13. 特集 身近に潜む心筋症を診る-進歩する診断と治療 [Chapter 5] 心筋症の治療管理 心不全薬物療法 Reviewed

    廣瀬 未来, 足立 史郎

    内科   Vol. 134 ( 2 ) page: 303 - 307   2024.8

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_naika134_303

    CiNii Research

  14. Clinical usefulness of endothelial progenitor cells in predicting the efficacy of riociguat in chronic thromboembolic pulmonary hypertension Reviewed Open Access

    Ryo Imai 1 2, Shiro Adachi 3, Masahiro Yoshida 1, Shigetake Shimokata 1, Yoshihisa Nakano 3, Naoki Okumura 1, Toyoaki Murohara 1, Takahisa Kondo 1 2

    Nagoya J Med Sci   Vol. 86 ( 2 ) page: 292 - 303   2024.5

     More details

  15. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study) Invited Reviewed Open Access

    Yuichi Tamura 1, Hiraku Kumamaru 2, Ichizo Tsujino 3, Rika Suda 4, Kohtaro Abe 5, Takumi Inami 6, Koshin Horimoto 7, Shiro Adachi 8, Satoshi Yasuda 9, Fusako Sera 10, Yu Taniguchi 11, Masataka Kuwana 12 13, Koichiro Tatsumi 4; Japan Pulmonary Hypertension Registry Network

    Pharmaceuticals (Basel) .   Vol. 17 ( 5 )   2024.4

     More details

  16. 特集 肺高血圧治療~今どこに進んでいるのか~ 診る7 日常診療に潜むCTEPHを見逃さないコツ Reviewed

    足立 史郎

    Heart View   Vol. 28 ( 4 ) page: 348 - 353   2024.4

     More details

    Publisher:メディカルレビュー社  

    DOI: 10.18885/hv.0000001527

    CiNii Research

  17. 特集 患者さんからよく尋ねられる内科診療のQuestion 第3章 循環器 [45歳男性,左室駆出率(LVEF)35%,拡張型心筋症]血圧が低いのに,なぜ血圧を下げる薬を飲まないといけないのでしょうか? Reviewed

    足立 史郎

    内科   Vol. 133 ( 4 ) page: 672 - 674   2024.4

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_naika133_672

    CiNii Research

  18. Detrimental Impact of Comorbid Mental Disorders in Chronic Thromboembolic Pulmonary Hypertension ― A Retrospective Observational Study ― Invited Open Access

    Adachi Takeshi, Adachi Shiro, Nakano Yoshihisa, Yasuda Kenichiro, Nishiyama Itsumure, Hirose Miku, Murohara Toyoaki

    Circulation Reports   Vol. 6 ( 3 ) page: 80 - 85   2024.3

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b> The relationship between the prognosis of patients with both chronic thromboembolic pulmonary hypertension (CTEPH) and a mental disorder (MD) remains unclear.</p><p><b><i>Methods and Results:</i></b> The study group comprised 157 patients with CTEPH who underwent right heart catheterization and were subdivided into 2 groups according to the presence of MDs: MD and non-MD. The patients with MDs were defined as those who had visited a psychiatrist and were under psychotropic drug treatment. The primary outcome was a composite of all-cause death and worsening of PH. The median follow-up period was 1,164 days. The incidence of the primary composite outcome was higher in the MD group than in the non-MD group (24.0% vs. 6.8%), whereas the all-cause mortality rate was comparable between groups (12.0% vs. 6.1%). The mean pulmonary arterial pressure, cardiac index, and pulmonary vascular resistance at baseline were all similar between groups. The Cox proportional hazards model indicated that MD was an independent risk factor for the primary composite outcome (hazard ratio, 2.990; 95% confidence interval, 1.034–8.642).</p><p><b><i>Conclusions:</i></b> In the present study, concomitant CTEPH and MD was significantly associated with a poor prognosis and such patients should be carefully followed.</p>

    DOI: 10.1253/circrep.CR-23-0074

    Open Access

    PubMed

    CiNii Research

  19. Mortality, Recurrent Thromboembolism and Major Bleeding in Cancer-Associated and Non-Cancer Pulmonary Embolism Patients Treated With Direct Oral Anticoagulants Open Access

    Nakano Yoshihisa, Adachi Shiro, Imai Ryo, Yoshida Masahiro, Shimokata Shigetake, Murohara Toyoaki, Kondo Takahisa

    Circulation Journal   Vol. 88 ( 2 ) page: 243 - 250   2024.1

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b>Pulmonary embolism (PE) is a potentially fatal form of venous thromboembolism (VTE). This study compares the mortality, incidence of recurrent VTE, and incidence of major bleeding between non-cancer and cancer-associated PE patients treated with direct oral anticoagulants (DOACs).</p><p><b><i>Methods and Results:</i></b>This was a retrospective, observational, single-center study involving 130 consecutive patients (87 with active cancer; 43 without cancer) who received DOAC treatment for PE between January 2016 and December 2019. Kaplan-Meier analysis showed significantly higher mortality in cancer-associated PE patients than in non-cancer patients (35/87 [40%] vs. 1/43 [2%], P<i><</i>0.001, log-rank test, HR 18.6 [95% CI: 2.5–136.0]). In contrast, the cumulative incidences of recurrent VTE and major bleeding were comparable between the 2 groups. Among the cancer-associated PE patients, the incidence for the composite outcome of recurrent VTE or major bleeding was significantly higher in patients undergoing chemotherapy than in those not undergoing chemotherapy (9/37 [24%] vs. 2/50 [4%], P=0.004, log-rank test, HR 6.9 [95% CI: 1.5–32.0]).</p><p><b><i>Conclusions:</i></b>Although cancer-associated PE patients treated with DOACs showed higher mortality compared with non-cancer patients, presumably because of the presence of cancer, the risk of recurrent VTE or major bleeding was comparable between the 2 groups. Thus, DOAC is an important treatment option for cancer-associated PE, although underlying cancer-related risks (e.g., chemotherapy) remain.</p>

    DOI: 10.1253/circj.CJ-20-1247

    Open Access

    PubMed

    CiNii Research

  20. Adult-onset idiopathic peripheral pulmonary artery stenosis. Reviewed Open Access

    Tamura Y, Tamura Y, Shigeta A, Hosokawa K, Taniguchi Y, Inami T, Adachi S, Tsujino I, Nakanishi N, Sato K, Sakamoto J, Tanabe N, Takama N, Nakamura K, Kubota K, Komura N, Kato S, Yamashita J, Takei M, Joho S, Ishii S, Takemura R, Sugimura K, Tatsumi K

    The European respiratory journal   Vol. 62 ( 6 )   2023.12

     More details

    Language:English  

    DOI: 10.1183/13993003.00763-2023

    PubMed

  21. 特集 変革期を迎えた肺高血圧症-次世代の病態理解,診断,治療とは? Ⅱ.各論:各種肺高血圧症の診断と治療 atypical PAHの病態と治療 Reviewed

    足立 史郎

    循環器ジャーナル   Vol. 71 ( 4 ) page: 523 - 528   2023.10

     More details

    Publisher:株式会社 医学書院  

    DOI: 10.11477/mf.1438200739

    CiNii Research

  22. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study Reviewed Open Access

    Kazuya Hosokawa 1, Kohtaro Abe 2, Kouta Funakoshi 3, Yuichi Tamura 4, Naoki Nakashima 5, Koji Todaka 3, Yu Taniguchi 6, Takumi Inami 7, Shiro Adachi 8, Ichizo Tsujino 9, Jun Yamashita 10, Shun Minatsuki 11, Nobutaka Ikeda 12, Hiroto Shimokawahara 13, Takashi Kawakami 14, Takeshi Ogo 15, Masaru Hatano 11, Hitoshi Ogino 16, Yoshihiro Fukumoto 17, Nobuhiro Tanabe 18, Hiromi Matsubara 13, Keiichi Fukuda 19, Koichiro Tatsumi 20, Hiroyuki Tsutsui 2

    J Thromb Haemost   Vol. 21 ( 8 ) page: 2151 - 2162   2023.8

  23. 特集 肺高血圧症 早期発見,早期診断にむけて 肺高血圧症とは? 肺高血圧症の早期診断と鑑別のポイント センター化の意義 Reviewed

    足立 史郎

    Medical Practice   Vol. 40 ( 5 ) page: 686 - 694   2023.5

     More details

    Publisher:(株)文光堂  

    DOI: 10.50936/j01778.2023205926

    CiNii Research

  24. SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol. Reviewed Open Access

    Tamura Y, Takeyasu R, Takata T, Miyazaki N, Takemura R, Wada M, Tamura Y, Abe K, Shigeta A, Taniguchi Y, Adachi S, Inami T, Tsujino I, Tahara N, Kuwana M

    Pulmonary circulation   Vol. 13 ( 2 ) page: e12251   2023.4

     More details

  25. 第1土曜特集 肺高血圧症のすべて--病態研究と治療法の最前線 各論 詳細不明な多因子のメカニズムによる肺高血圧症の実態にせまる Reviewed

    足立 史郎

    医学のあゆみ   Vol. 284 ( 5 ) page: 392 - 398   2023.2

     More details

    Publisher:医歯薬出版  

    DOI: 10.32118/ayu28405392

    CiNii Research

  26. SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol Reviewed Open Access

    Yuichi Tamura 1 2, Rika Takeyasu 1, Tomohiro Takata 3, Naoki Miyazaki 4, Ryo Takemura 4, Michihiko Wada 4, Yudai Tamura 1 2, Kohtaro Abe 5, Ayako Shigeta 6, Yu Taniguchi 7, Shiro Adachi 8, Takumi Inami 9, Ichizo Tsujino 10, Nobuhiro Tahara 11, Masataka Kuwana 12

    Pulm Circ .   Vol. 13 ( 2 )   2023

     More details

    Language:English  

    DOI: 10.1002/pul2.12251.

    Open Access

  27. Clinical Management and Outcomes of Patients With Portopulmonary Hypertension Enrolled in the Japanese Multicenter Registry Open Access

    Tamura Yudai, Tamura Yuichi, Taniguchi Yu, Tsujino Ichizo, Inami Takumi, Matsubara Hiromi, Shigeta Ayako, Sugiyama Yoichi, Adachi Shiro, Abe Kohtaro, Baba Yuichi, Hatano Masaru, Ikeda Satoshi, Kusunose Kenya, Sugimura Koichiro, Usui Soichiro, Takeishi Yasuchika, Dohi Kaoru, Hasegawa-Tamba Saki, Horimoto Koshin, Kikuchi Noriko, Kumamaru Hiraku, Tatsumi Koichiro, on behalf of the Japan Pulmonary Hypertension Registry Network

    Circulation Reports   Vol. 4 ( 11 ) page: 542 - 549   2022.11

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b> Portopulmonary hypertension (PoPH) is one of the major underlying causes of pulmonary arterial hypertension (PAH). However, PoPH, especially treatment strategies, has been poorly studied. Therefore, this study evaluated current treatments for PoPH, their efficacy, and clinical outcomes of patients with PoPH.</p><p><b><i>Methods and Results:</i></b> Clinical data were collected for patients with PoPH who were enrolled in the Japan Pulmonary Hypertension Registry between 2008 and 2021. Hemodynamic changes, functional class, and clinical outcomes were compared between patients with PoPH treated with monotherapy and those treated with combination therapies. Clinical data were analyzed for 62 patients with PoPH, including 25 treatment-naïve patients, from 21 centers in Japan. In more than half the patients, PAH-specific therapy improved the New York Heart Association functional class by at least one class. The 3- and 5-year survival rates of these patients were 88.5% (95% confidence interval [CI] 76.0–94.7) and 80.2% (95% CI 64.8–89.3), respectively. Forty-one (66.1%) patients received combination therapy. Compared with patients who had received monotherapy, the mean pulmonary arterial pressure, pulmonary vascular resistance, and cardiac index were significantly improved in patients who had undergone combination therapies.</p><p><b><i>Conclusions:</i></b> Combination therapy was commonly used in patients with PoPH with a favorable prognosis. Combination therapies resulted in significant hemodynamic improvement without an increased risk of side effects.</p>

    DOI: 10.1253/circrep.CR-22-0098

    Open Access

    PubMed

    CiNii Research

  28. Right ventricular pressure overload related to residual thrombotic burden in patients 1 year after acute pulmonary embolism: From the Nagoya PE study. Reviewed Open Access

    Nakano Y, Adachi S, Nishiyama I, Yasuda K, Yoshida M, Iwano S, Kondo T, Murohara T

    Thrombosis research   Vol. 216   page: 113 - 119   2022.8

  29. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy. Reviewed

    Adachi S, Nishiyama I, Yasuda K, Yoshida M, Nakano Y, Kondo T, Murohara T

    Journal of cardiology cases   Vol. 26 ( 1 ) page: 42 - 45   2022.7

     More details

    Language:English  

    DOI: 10.1016/j.jccase.2022.02.003

    PubMed

  30. Right Ventricular Dyssynchrony Casts New Light on the Risk Stratification and Prediction of Prognosis in Patients With Pulmonary Hypertension. Reviewed Open Access

    Adachi S, Nakano Y, Furusawa K

    Circulation journal : official journal of the Japanese Circulation Society   Vol. 86 ( 6 ) page: 945 - 946   2022.5

     More details

  31. Implications of Pulmonary Artery Wave Reflection in Patients With Pulmonary Hypertension. Reviewed Open Access

    Nakano Y, Adachi S

    Circulation journal : official journal of the Japanese Circulation Society   Vol. 86 ( 6 ) page: 956 - 957   2022.5

     More details

  32. End-Systolic Eccentricity Index Obtained by Enhanced Computed Tomography Is a Predictor of Pulmonary Vascular Resistance in Patients with Chronic Thromboembolic Pulmonary Hypertension. Reviewed Open Access

    Tsutsumi Y, Adachi S, Nakano Y, Iwano S, Abe S, Kato K, Naganawa S

    Life (Basel, Switzerland)   Vol. 12 ( 4 )   2022.4

     More details

  33. 特集 1ページでわかる内科疾患の診療ノート-"あたりまえ" のなかにある大事な視点 第2章:循環器 肺高血圧症 Reviewed

    足立 史郎

    内科   Vol. 129 ( 4 ) page: 603 - 606   2022.4

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_naika129_603

    CiNii Research

  34. Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study. Reviewed Open Access

    Nakano Y, Adachi S, Nishiyama I, Yasuda K, Imai R, Yoshida M, Iwano S, Kondo T, Murohara T

    Journal of thrombosis and haemostasis : JTH   Vol. 20 ( 4 ) page: 888 - 898   2022.4

     More details

  35. Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy. Reviewed Open Access

    Yasuda K, Adachi S, Nishiyama I, Yoshida M, Nakano Y, Murohara T

    Pulmonary circulation   Vol. 12 ( 2 ) page: e12074   2022.4

     More details

  36. 山本論文に対するEditorial Comment Reviewed

    足立 史郎

    心臓   Vol. 54 ( 1 ) page: 113 - 114   2022.1

     More details

    Language:Japanese   Publisher:公益財団法人 日本心臓財団  

    DOI: 10.11281/shinzo.54.113

    CiNii Research

  37. Pulmonary tumor thrombotic microangiopathy with thrombus in pulmonary artery caused by diffuse sclerosing variant of thyroid papillary adenocarcinoma: A case report. Reviewed Open Access

    Yoshida M, Adachi S, Nishiyama I, Yasuda K, Imai R, Nakano Y, Tsuyuki Y, Kim D, Kondo T, Murohara T

    Pulmonary circulation   Vol. 12 ( 1 ) page: e12027   2022.1

     More details

  38. Left Upper Lobe Trisegmentectomy After Pulmonary Endarterectomy. Reviewed

    Tsubouchi H, Goto M, Terazawa S, Adachi S, Suzuki Y, Usui A, Kondo T, Chen-Yoshikawa TF

    The Annals of thoracic surgery   Vol. 112 ( 5 ) page: e361 - e363   2021.11

     More details

  39. <Editors' Choice> Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population. Reviewed Open Access

    Yoshida M, Adachi S, Imai R, Shimokata S, Nakano Y, Murohara T, Kondo T

    Nagoya journal of medical science   Vol. 83 ( 2 ) page: 321 - 330   2021.5

     More details

  40. Endostatin and Vascular Endothelial Growth Factor-A<sub>165</sub>b May Contribute to Classification of Pulmonary Hypertension Open Access

    Adachi Shiro, Kikuchi Ryosuke, Shimokata Shigetake, Suzuki Atsuo, Yoshida Masahiro, Imai Ryo, Nakano Yoshihisa, Kondo Takahisa, Murohara Toyoaki

    Circulation Reports   Vol. 3 ( 3 ) page: 161 - 169   2021.2

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b>Pulmonary hypertension (PH) is characterized by dysregulation of small pulmonary arteries. In addition to endostatin (ES), placenta growth factor (PlGF), vascular endothelial growth factor-A (VEGF-A), and the anti-angiogenesis isoform of VEGF-A (VEGF-A<sub>165</sub>b) are associated with PH. However, the usefulness of these biomarkers in PH in unknown. We investigated whether these 4 biomarkers are related to PH classification.</p><p><b><i>Methods and Results:</i></b>Between July 2015 and August 2017, 33 control patients and 107 PH patients were enrolled in the study. Among the PH patients, 48 had pulmonary arterial hypertension (PAH), 5 had left heart disease-associated PH (LHD-PH), 4 had lung disease-associated PH (LD-PH), and 50 had chronic thromboembolic PH (CTEPH). Among the PAH patients, 16 had idiopathic PAH (IPAH) and 17 had connective tissue disease-associated PAH (CTD-PAH). PlGF, total VEGF-A, and VEGF-A<sub>165</sub>b levels were measured in the control and PH groups. ES was only measured in the PH group. VEGF-A<sub>165</sub>b levels were significantly higher in the LD-PH group than in the PAH, LHD-PH, and CTEPH groups (all P<0.001). PlGF levels were significantly higher in the CTD-PAH group than in the IPAH and control groups. ES levels were significantly correlated with the 6-min walk distance (P<0.001), B-type natriuretic peptide (P<0.001), and pulmonary vascular resistance (P=0.008).</p><p><b><i>Conclusions:</i></b>ES could detect CTD-PAH in PAH and may be an indicator of PH severity. VEGF-A<sub>165</sub>b was useful in detecting LD-PH.</p>

    DOI: 10.1253/circrep.CR-20-0096

    Open Access

    PubMed

    CiNii Research

  41. 特集 高齢者における循環器診療 トピックス 高齢者における肺高血圧症 Reviewed

    足立 史郎

    内科   Vol. 126 ( 5 ) page: 961 - 964   2020.11

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_naika126_961

    CiNii Research

  42. Clinical course of pulmonary embolism patients treated with DOACs: comparing prognosis, recurrent thromboembolism, and major bleeding between patients with and without cancer

    Nakano Y., Imai R., Yoshida M., Shimokata S., Adachi S., Murohara T., Kondo T.

    EUROPEAN HEART JOURNAL   Vol. 41   page: 2279 - 2279   2020.11

     More details

    Language:Japanese  

    Web of Science

  43. Potential of Selexipag in Chronic Thromboembolic Pulmonary Hypertension Medical Therapy Open Access

    Kondo Takahisa, Nakano Yoshihisa, Adachi Shiro

    Circulation Journal   Vol. 84 ( 10 ) page: 1691 - 1692   2020.9

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b>Selexipag is an oral prostacyclin receptor (IP receptor) agonist with a non-prostanoid structure. This study examined its efficacy and safety in Japanese patients with non-operated or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).</p><p><b><i>Methods and Results:</i></b>This Phase II study was a randomized, double-blind, placebo-controlled parallel-group comparison. The primary endpoint was a change in pulmonary vascular resistance (PVR) from baseline to week 17. The main analysis involved a per-protocol set group of 28 subjects. The change in PVR (mean±SD) after 17 weeks of treatment in the selexipag group was −104±191 dyn·s/cm<sup>5</sup>, whereas that in the placebo group was 26±180 dyn·s/cm<sup>5</sup>. Thus, the treatment effect after 17 weeks of selexipag treatment was calculated as −130±189 dyn·s/cm<sup>5</sup>(P=0.1553). Although the primary endpoint was not met, for the group not concomitantly using a pulmonary vasodilator the PVR in the selexipag group was significantly decreased compared with placebo group (P=0.0364). The selexipag group also showed improvement in total pulmonary resistance and cardiac index.</p><p><b><i>Conclusions:</i></b>Selexipag treatment improved pulmonary hemodynamics in Japanese patients with CTEPH, but PVR did not show a significant difference between the selexipag and placebo groups. (Trial registration: JAPIC Clinical Trials Information [JapicCTI-111667])</p>

    DOI: 10.1253/circj.CJ-20-0879

    Open Access

    Web of Science

    PubMed

    CiNii Research

  44. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan

    Imai Ryo, Adachi Shiro, Yoshida Masahiro, Shimokata Shigetake, Nakano Yoshihisa, Okumura Naoki, Murohara Toyoaki, Kondo Takahisa

    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY   Vol. 98 ( 9 ) page: 653 - 658   2020.9

     More details

    Language:Japanese  

    Web of Science

  45. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.

    Imai R, Adachi S, Yoshida M, Shimokata S, Nakano Y, Okumura N, Murohara T, Kondo T

    Canadian journal of physiology and pharmacology   Vol. 98 ( 9 ) page: 653 - 658   2020.9

     More details

    Language:English  

    DOI: 10.1139/cjpp-2019-0640

    PubMed

  46. Risk of Pulmonary Arterial Hypertension During Qing-Dai Use for the Treatment of Ulcerative Colitis Open Access

    Adachi Shiro, Nakano Yoshihisa, Kondo Takahisa

    Circulation Journal   Vol. 84 ( 8 ) page: 1235 - 1236   2020.7

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b>Qing-Dai (QD) treatment of patients with ulcerative colitis (UC) sometimes causes pulmonary arterial hypertension (PAH). However, the relationship of QD treatment to pulmonary arterial systolic pressure (PASP) in patients with UC has not been clarified.</p><p><b><i>Methods and Results:</i></b>The 27 patients with UC who were screened for PAH by transthoracic echocardiography (TTE) and underwent repeat TTE at 1 year were analyzed in this prospective observational study. Mean age was 44.0 years old, and median follow-up duration was 392. During the follow-up, 21 patients continued QD treatment (continuous group) and 6 patients discontinued the treatment (discontinuous group). In all patients, no significant difference in PASP levels between baseline and at follow-up was observed (21.4 vs. 21.3 mmHg, P=0.802). Furthermore, the mean PASP of patients in the continuous group did not differ from baseline to follow-up (21.4 mmHg to 22.6 mmHg, P=0.212); however, in the discontinuous group mean PASP was significantly decreased (21.5 mmHg to 16.8 mmHg, P=0.005). Moreover, changes in PASP from baseline to follow-up differed between the continuous and discontinuous groups (+1.1 mmHg vs. −4.7 mmHg, P=0.004). In addition, multivariable analyses revealed that only the duration of oral QD at baseline affected the increase of PASP.</p><p><b><i>Conclusions:</i></b>In patients with UC, QD treatment may have an undesirable association with an increase in PASP.</p>

    DOI: 10.1253/circj.CJ-20-0621

    Open Access

    Web of Science

    PubMed

    CiNii Research

  47. Assessment of Severity in Chronic Thromboembolic Pulmonary Hypertension by Quantitative Parameters of Dual-Energy Computed Tomography Reviewed Open Access

    Tsutsumi, Y; Iwano, S; Okumura, N; Adachi, S; Abe, S; Kondo, T; Kato, K; Naganawa, S

    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY   Vol. 44 ( 4 ) page: 578 - 585   2020.7

  48. Automatic Remasking of Digital Subtraction Angiography Images in Pulmonary Angiography Reviewed Open Access

    Mizukuchi, T; Uemura, T; Kondo, S; Abe, S; Adachi, S; Okumura, N; Kondo, T; Koyama, S

    JOURNAL OF DIGITAL IMAGING   Vol. 33 ( 2 ) page: 531 - 537   2020.4

     More details

  49. Addition of a bilateral access form of peripheral extracorporeal membrane oxygenation rescued a patient with idiopathic pulmonary arterial hypertension who developed circulatory collapse immediately after childbirth Reviewed Open Access

    Adachi, S; Shimokata, S; Yoshida, M; Imai, R; Nakano, Y; Okumura, N; Suzuki, S; Murohara, T; Kondo, T

    PULMONARY CIRCULATION   Vol. 10 ( 1 ) page: 2045894020910140   2020.1

     More details

  50. Effects of Tobacco Smoking on Cardiovascular Disease Open Access

    Kondo Takahisa, Nakano Yoshihisa, Adachi Shiro, Murohara Toyoaki

    CIRCULATION JOURNAL   Vol. 83 ( 10 ) page: 1980 - 1985   2019.10

     More details

  51. A Lethal Case due to Progressive Pulmonary Hypertension Presenting with Mediastinal, Hilar and Inguinal Lymphadenopathy and Pulmonary Interstitial Shadow on Chest CT

    Shimizu Shinya, Adachi Shiro, Goto Yasuhiro, Itoh Shigeki, Shimano Masayuki, Nagase Michitaka, Ito Masafumi, Ito Ai, Yoshitomi Atsushi, Haruta Junichi, Sakanoue Yuji, Shikino Kiyoshi, Sunaga Shinji

    Nihon Naika Gakkai Zasshi   Vol. 108 ( 9 ) page: 1985 - 2004   2019.9

     More details

    Language:Japanese   Publisher:The Japanese Society of Internal Medicine  

    DOI: 10.2169/naika.108.1985

    CiNii Research

  52. Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity Reviewed Open Access

    Hirashiki, A; Adachi, S; Okumura, N; Nakano, Y; Shimokata, S; Shimizu, A; Arai, H; Toba, K; Murohara, T; Kondo, T

    HEALTH AND QUALITY OF LIFE OUTCOMES   Vol. 17 ( 1 ) page: 103   2019.6

  53. Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension ― Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE) ― Open Access

    Hirashiki Akihiro, Kondo Takahisa, Adachi Shiro, Nakano Yoshihisa, Kamimura Yoshihiro, Shimokata Shigetake, Okumura Naoki, Shimizu Atsuya, Washimi Yukihiko, Arai Hidenori, Murohara Toyoaki, on behalf of the GOOD EYE Investigators

    Circulation Reports   Vol. 1 ( 7 ) page: 303 - 311   2019.6

     More details

    Language:English   Publisher:The Japanese Circulation Society  

    <p><b><i>Background:</i></b>Many treatment options are available for pulmonary arterial hypertension (PAH), but specific recommendations for long-term treatment are unavailable. We compared prognosis in PAH patients receiving goal-oriented, sequential combination therapy evaluated using cardiopulmonary exercise testing (CPX) parameters or conventional empiric therapy.</p><p><b><i>Methods and Results:</i></b>The <u>Go</u>al-<u>O</u>riente<u>d</u> Therapy <u>E</u>valuated b<u>y</u> Cardiopulmonary <u>E</u>xercise Testing for Pulmonary Arterial Hypertension (GOOD EYE) study was a multicenter, retrospective/prospective study in which a total of 129 patients with newly diagnosed PAH were enrolled (goal-oriented sequential combination therapy, n=42; conventional empiric therapy, n=87). Patients in the goal-oriented therapy group received sequential combination therapy, the efficacy of which was regularly evaluated using CPX parameters. Patients in the conventional empiric therapy group received conventional empiric therapy. The primary endpoint was cardiovascular death. In the goal-oriented therapy group, plasma brain natriuretic peptide, mean pulmonary arterial pressure, pulmonary vascular resistance, and 6-min walk test were significantly improved at 12 months compared with baseline. Survival in the goal-oriented therapy group at 1, 2, and 3 years (97.6%, 95.2%, and 86.0%, respectively) tended to be higher than that in the conventional empiric therapy group (P=0.082).</p><p><b><i>Conclusions:</i></b>Goal-oriented sequential combination therapy evaluated using CPX parameters may be associated with a favorable prognosis compared with conventional empiric therapy in patients with newly diagnosed PAH.</p>

    DOI: 10.1253/circrep.CR-19-0047

    Open Access

    PubMed

    CiNii Research

  54. Renin Activity as a Key Predictor of Major Adverse Cardiac Events Open Access

    Kondo Takahisa, Nakano Yoshihisa, Adachi Shiro, Murohara Toyoaki

    CIRCULATION JOURNAL   Vol. 83 ( 6 ) page: 1204 - 1205   2019.6

     More details

  55. Pulmonary Hypertension: Diagnosis, Management, and Treatment Reviewed Open Access

    Kondo, T; Okumura, N; Adachi, S; Murohara, T

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 1 ) page: 19 - 30   2019.2

     More details

  56. Usefulness of scoring right ventricular function for assessment of prognostic factors in patients with chronic thromboembolic pulmonary hypertension Reviewed Open Access

    Kamimura, Y; Okumura, N; Adachi, S; Shimokata, S; Tajima, F; Nakano, Y; Hirashiki, A; Murohara, T; Kondo, T

    HEART AND VESSELS   Vol. 33 ( 10 ) page: 1220 - 1228   2018.10

     More details

  57. Left ventricular end-diastolic dimension and septal e' are predictors of cardiac index at rest, while tricuspid annular plane systolic excursion is a predictor of peak oxygen uptake in patients with pulmonary hypertension Reviewed Open Access

    Nakano, Y; Okumura, N; Adachi, S; Shimokata, S; Tajima, F; Kamimura, Y; Murohara, T; Kondo, T

    HEART AND VESSELS   Vol. 33 ( 5 ) page: 521 - 528   2018.5

     More details

  58. Left ventricular end-diastolic dimension, septal e prime and tricuspid annular plane systolic excursion are useful for evaluating conditions of patients with pulmonary hypertension Reviewed

    Nakano, Y; Okumura, N; Adachi, S; Shimokata, S; Kamimura, Y; Tajima, F; Murohara, T; Kondo, T

    EUROPEAN HEART JOURNAL   Vol. 38   page: 1151 - 1151   2017.8

     More details

    Language:Japanese  

    Web of Science

  59. Effects of balloon pulmonary angioplasty were modest in patients with inoperable central-type chronic thromboembolic pulmonary hypertension Reviewed

    Adachi, S; Okumura, N; Tajima, F; Shimokata, S; Kamimura, Y; Nakano, Y; Murohara, T; Kondo, T

    EUROPEAN HEART JOURNAL   Vol. 38   page: 1079 - 1080   2017.8

     More details

    Language:Japanese  

    Web of Science

  60. Left main coronary artery compression by a dilated main pulmonary artery and left coronary sinus of Valsalva aneurysm in a patient with heritable pulmonary arterial hypertension and FLNA mutation Reviewed Open Access

    Hirashiki, A; Adachi, S; Nakano, Y; Kamimura, Y; Ogo, T; Nakanishi, N; Morisaki, T; Morisaki, H; Shimizu, A; Toba, K; Murohara, T; Kondo, T

    PULMONARY CIRCULATION   Vol. 7 ( 3 ) page: 734 - 740   2017.7

     More details

  61. Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension Reviewed Open Access

    Hirashiki, A; Adachi, S; Nakano, Y; Kamimura, Y; Shimokata, S; Takeshita, K; Shimizu, A; Toba, K; Murohara, T; Kondo, T

    PULMONARY CIRCULATION   Vol. 7 ( 2 ) page: 448 - 454   2017.4

     More details

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. 肺細動脈内皮細胞で特徴的変化を示す分子に着目した肺高血圧症への新規治療戦略の開発

    Grant number:22K08123  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    加藤 勝洋, 足立 史郎, 室原 豊明

      More details

    Authorship:Coinvestigator(s) 

    肺動脈性肺高血圧症(PAH)は指定難病の1つであり、肺血管拡張薬の開発により患者の短期予後は以前より改善したものの、治療が奏功しない症例も多く、新規治療薬および診断バイオマーカーの開発が急務である。PAHにおいて、なぜ全身の血管ではなく、末梢側の肺細動脈のみで異常をきたすのかは解っていない。本研究では、全身の動脈と比較して、肺細動脈で特徴的な発現変動を示す分子に着目し、培養細胞、個体、患者臨床検体と組み合わせて、病態を解き明かす。本研究によって、PAHの病理の具体的発症メカニズムの理解を深め、新規治療戦略をもたらすことができる。
    肺高血圧症は、全身の血管網ではなく主病変部である肺細動脈局所のシグナル異常が発端とした疾患であることが予測され、現在までに行なった網羅的スクリーニングの結果、肺細動脈内皮細胞特異的に発現する分子A、分子Bを見出してきた。これらの分子の解析を通して、肺高血圧症の疾患制御機構の解明や創薬を含む治療戦略の開発、早期診断のためのバイオマーカーの開発につなげることを目的としている。現時点で以下のような実験の結果を得ている。
    1、培養肺動脈内皮細胞を用いて分子A及び分子BをsiRNAを用いたノックダウンやレンチウイルスを用いた過剰発現を行い、BMP/TGF-β/Smad、MAPキナーゼ、PI3K/Aktなどの細胞内シグナルの検証を行なっている。また、低酸素曝露した際の分子A及び分子Bの発現変化について検証し、分子Bに関しては発現の低下を認めた。
    2、分子Aまたは分子Bに対する遺伝子欠損マウスの作成を進めた。分子Aに対する遺伝子欠損マウスに関して、解析を進めているが現時点では有意な変化を認めていない。分子Aまたは分子Bをマウス個体で過剰発現させるためのアデノ随伴ウイルスの作成を進め、分子Aの過剰発現に関しては有意な変化を認めなかった。
    3、肺高血圧症の病態解明およびバイオマーカーの可能性を検証するために、肺高血圧症患者に対して右心カテーテル検査を実施する際に血液検体の採取を行なっている。肺動脈の前後で血中濃度を比較検討するために、肺動脈と左心室より血液検体の採取・保存している。現在までに101人の肺高血圧症患者より血液検体の採取を完了した。分子Aに関して、13症例の検体で測定を行い、平均肺動脈圧と混合静脈血酸素飽和濃度と相関の可能性が示唆された。
    本年度は、培養肺動脈内皮細胞を用いた分子A及び分子Bの機能について評価を進めている。さらに個体での遺伝子の影響を評価するために、分子Aまたは分子Bに対する遺伝子欠損マウスの開発を進めており、分子Aに関しては解析も進んでいる。また、肺高血圧患者血液検体の収集、解析も進めており、これらの到達度は当初の研究計画の予定を考えると順調であると考えられる。
    引き続き、培養肺動脈内皮細胞を用いて分子A及び分子Bを中心とした細胞内シグナル伝達への修飾作用について評価を進めるとともに平滑筋細胞や線維芽細胞への影響を評価する。作製した遺伝子欠損マウスの個体での解析を進める。収集した肺高血圧症患者の血液検体の解析を進める。

  2. Severity index of chronic thromboembolic pulmonary hypertension

    Grant number:20K17075  2020.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    Adachi Shiro

      More details

    Authorship:Principal investigator 

    Grant amount:\2600000 ( Direct Cost: \2000000 、 Indirect Cost:\600000 )

    The refined CT imaging method made it easier to see the thrombus in the periphery of the pulmonary artery, it was found that the residual thrombus after acute pulmonary embolism was 74%. It was found that the residual thrombus 1 month after acute pulmonary embolism is a risk factor, and it is important to follow up carefully for the group of patients with residual thrombus. The transition to chronic thromboembolic pulmonary hypertension (CTEPH) was 3.8%. Furthermore, although the amount of thrombus at the time of diagnosis of CTEPH is not related to the severity, it was found to be useful for determining the therapeutic effect of pulmonary vasodilators and catheter treatment. In addition, low thrombus volume may indicate relatively advanced pulmonary artery degeneration, suggesting that pulmonary vasodilators are more useful than catheterization in such groups.

  3. Role of VEGF165b, an inhibitory vascular endothelial growth factor splice variant, in pulmonary hypertension

    Grant number:17K09551  2017.4 - 2020.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Kondo Takahisa

      More details

    Authorship:Coinvestigator(s) 

    Pulmonary hypertension (PH) is a pathophysiological disorder that involves dysregulated proliferation of pulmonary arterial endothelial cells and of smooth muscle cells, resulting in an increase in pulmonary vascular resistance, right-sided heart failure and death. In patients with advanced PH, dysfunctional angiogenesis is one of the main mechanisms of disease progression. Therefore, understanding the balance between angiogenic and antiangiogenic factors is important. In the present study, Role of VEGF165b, an inhibitory vascular endothelial growth factor splice variant, were investigated. In lung disease associated PH (LD-PH), serum levels of VEGF165b were elevated. Among patients with pulmonary arterial hypertension (PAH), serum levels of VEGF165b were elevated in PAH associated with connective tissue disease. VEGF165b may be involved in the pathophysiological disorder of LD-PH and PAH associated with connective tissue disease.

  4. The role of VEGF in pulmonary hypertension

    Grant number:17K15997  2017.4 - 2019.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    Adachi Shiro, Murohara Toyoaki, Kondo Takahisa, Nakano Yoshihisa, Kikuchi Ryosuke, Shimokata Shigetake

      More details

    Authorship:Principal investigator 

    Grant amount:\2600000 ( Direct Cost: \2000000 、 Indirect Cost:\600000 )

    Pulmonary hypertension is severe condition with stenosis of pulmonary artery leading to lethal heart failure. VEGF has a potential relating to this stenosis, obstruction. Therefore, the aim of this study was to clarify roles of VEGF-A and VEGF-A165b on pulmonary hypertension. VEGF-165 and VEGF-165b were significantly increased in patients with pulmonary hypertension compared to control. in the sub-analysis that verified the difference among etiology of pulmonary hypertension, VEGF-A and VEGF-165b were significantly increased in chronic thromboembolic pulmonary hypertension and connective tissue disease associated pulmonary hypertension compared to other etiologies. VEGF-A and 165b was useful